Effectiveness of Additional Risk Minimization Measures Related to Interstitial Lung Disease/Pneumonitis With Trastuzumab Deruxtecan Treatment of Breast Cancer in European Countries: Results and Learnings From a Post‐Authorization Safety Survey Among Physicians
Pharmacoepidemiology and Drug Safety · 2025
DOI: 10.1002/pds.70206 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2025. Verfasst von Angelika Wientzek-Fleischmann und 4 weiteren Autor:innen. Beteiligte Einrichtung: Daiichi-Sankyo Europe GmbH, Munich, Germany. Hauptthemen laut MEDLINE: Lung Diseases, Interstitial, Breast Neoplasms, Trastuzumab, Practice Patterns, Physicians'. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Daiichi Sankyo Europe GmbH, Munich, Germany, Daiichi Sankyo Europe.
Abstract (Originalsprache)
Background
Interstitial lung disease ( ILD )/pneumonitis is an important safety risk of trastuzumab deruxtecan (T‐ DXd ) treatment. This study assessed the effectiveness of additional risk minimization measures ( aRMMs ) outlined in the educational material ( EM ) for the product regarding physicians' awareness, knowledge, and implementation related to the risk, early detection, and management of ILD /pneumonitis.
Methods
A web‐based survey was conducted among prescribers of T‐ DXd from seven European countries (Austria, Denmark, France, Germany, Sweden, Spain, and the UK ) between 03/2021 and 11/2022. The overall effectiveness of the aRMMs was determined as the percentage of physicians correctly responding to questions in the awareness, knowledge, and implementation domains, with cut‐off thresholds of ≥ 80%, ≥ 60%, and ≥ 75%, respectively.
Results
Overall, 172 prescribing physicians from seven countries completed the survey questionnaire (response rate: 3.1%). The majority (73.8%) of the physicians acknowledged receiving EMs . In all, 91.6%, 46.7%, and 76.7% of the physicians correctly responded to questions in the awareness, knowledge, and implementation domains, respectively. The low score observed in the knowledge domain was primarily because the respondents did not acknowledge fever as a typical symptom of ILD /pneumonitis. When a post hoc sensitivity analysis was performed where “fever” was not classified as a mandatory answer to the question about typical symptoms for ILD /pneumonitis, the proportion of physicians achieving the threshold increased to 68.6%.
Conclusion
The aRMMs effectively imparted awareness and supported the management of T‐ DXd ‐induced ILD /pneumonitis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Daiichi-Sankyo Europe GmbH, Munich, Germany.
- IQVIA, Munich, Germany.
ORCID-Profile: Angelika Wientzek-Fleischmann, Annegret Gohlke, Birgit Ehlken
Förderung
- Daiichi Sankyo Europe GmbH, Munich, Germany
- Daiichi Sankyo Europe
Zitieren
APA
Wientzek-Fleischmann, A., Stellmacher, U., Beyerlein, E., Gohlke, A., & Ehlken, B. (2025). Effectiveness of Additional Risk Minimization Measures Related to Interstitial Lung Disease/Pneumonitis With Trastuzumab Deruxtecan Treatment of Breast Cancer in European Countries: Results and Learnings From a Post‐Authorization Safety Survey Among Physicians. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70206
Vancouver
Wientzek-Fleischmann A, Stellmacher U, Beyerlein E, Gohlke A, Ehlken B. Effectiveness of Additional Risk Minimization Measures Related to Interstitial Lung Disease/Pneumonitis With Trastuzumab Deruxtecan Treatment of Breast Cancer in European Countries: Results and Learnings From a Post‐Authorization Safety Survey Among Physicians. Pharmacoepidemiology and Drug Safety. 2025. doi:10.1002/pds.70206
BibTeX
@article{WientzekFleischmann2025,
author = {Wientzek-Fleischmann, Angelika and Stellmacher, Ulf and Beyerlein, Elisabeth and Gohlke, Annegret and Ehlken, Birgit},
title = {Effectiveness of Additional Risk Minimization Measures Related to Interstitial Lung Disease/Pneumonitis With Trastuzumab Deruxtecan Treatment of Breast Cancer in European Countries: Results and Learnings From a Post‐Authorization Safety Survey Among Physicians},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2025},
doi = {10.1002/pds.70206}
}
EUVIMED